1
|
Schmidt DJ, Pickett BE, Camacho D, Comach G, Xhaja K, Lennon NJ, Rizzolo K, de Bosch N, Becerra A, Nogueira ML, Mondini A, da Silva EV, Vasconcelos PF, Muñoz-Jordán JL, Santiago GA, Ocazionez R, Gehrke L, Lefkowitz EJ, Birren BW, Henn MR, Bosch I. A phylogenetic analysis using full-length viral genomes of South American dengue serotype 3 in consecutive Venezuelan outbreaks reveals a novel NS5 mutation. Infect Genet Evol 2011; 11:2011-9. [PMID: 21964598 PMCID: PMC3565618 DOI: 10.1016/j.meegid.2011.09.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Revised: 09/05/2011] [Accepted: 09/08/2011] [Indexed: 11/24/2022]
Abstract
Dengue virus currently causes 50-100 million infections annually. Comprehensive knowledge about the evolution of Dengue in response to selection pressure is currently unavailable, but would greatly enhance vaccine design efforts. In the current study, we sequenced 187 new dengue virus serotype 3 (DENV-3) genotype III whole genomes isolated from Asia and the Americas. We analyzed them together with previously-sequenced isolates to gain a more detailed understanding of the evolutionary adaptations existing in this prevalent American serotype. In order to analyze the phylogenetic dynamics of DENV-3 during outbreak periods; we incorporated datasets of 48 and 11 sequences spanning two major outbreaks in Venezuela during 2001 and 2007-2008, respectively. Our phylogenetic analysis of newly sequenced viruses shows that subsets of genomes cluster primarily by geographic location, and secondarily by time of virus isolation. DENV-3 genotype III sequences from Asia are significantly divergent from those from the Americas due to their geographical separation and subsequent speciation. We measured amino acid variation for the E protein by calculating the Shannon entropy at each position between Asian and American genomes. We found a cluster of seven amino acid substitutions having high variability within E protein domain III, which has previously been implicated in serotype-specific neutralization escape mutants. No novel mutations were found in the E protein of sequences isolated during either Venezuelan outbreak. Shannon entropy analysis of the NS5 polymerase mature protein revealed that a G374E mutation, in a region that contributes to interferon resistance in other flaviviruses by interfering with JAK-STAT signaling was present in both the Asian and American sequences from the 2007-2008 Venezuelan outbreak, but was absent in the sequences from the 2001 Venezuelan outbreak. In addition to E, several NS5 amino acid changes were unique to the 2007-2008 epidemic in Venezuela and may give additional insight into the adaptive response of DENV-3 at the population level.
Collapse
Affiliation(s)
- DJ Schmidt
- University of Massachusetts Medical School, Worcester, MA, US. Current address DJS: Tuft University Veternary School, North Grafton, MA
| | - BE Pickett
- University of Alabama at Birmingham, Birmingham, AL. Current address BEP: University of Texas Southwestern Medical Center, Dallas, TX, US
| | - D Camacho
- Biomed, Universidad de Carabobo, Maracay, Venezuela
| | - G Comach
- Biomed, Universidad de Carabobo, Maracay, Venezuela
| | - K Xhaja
- University of Massachusetts Medical School, Worcester, MA, US. Current address DJS: Tuft University Veternary School, North Grafton, MA
| | | | - K Rizzolo
- University of Massachusetts Medical School, Worcester, MA, US. Current address DJS: Tuft University Veternary School, North Grafton, MA
- Broad Institute. Cambridge, MA, US
| | - N de Bosch
- Banco Metropolitano de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
| | - A Becerra
- University of Massachusetts Medical School, Worcester, MA, US. Current address DJS: Tuft University Veternary School, North Grafton, MA
- Banco Metropolitano de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
| | - ML Nogueira
- Faculdade de Medicina de São José do Rio Preto, Laboratório de Pesquisas em Virologia, Departamento de Doenças Infecciosas e Parasitárias, São José do Rio Preto, SP, Brazil
| | - A Mondini
- Faculdade de Medicina de São José do Rio Preto, Laboratório de Pesquisas em Virologia, Departamento de Doenças Infecciosas e Parasitárias, São José do Rio Preto, SP, Brazil
| | - EV da Silva
- Instituto Nacional de Ciência e Tecnologia em Dengue, Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Bioquímica e Imunologia, Belo Horizonte and Instituto Nacional de Ciência e Tecnologia para Febres Hemorrágicas Virais (INCT-FHV), Instituto Evandro Chagas, Ministério da Saúde, Ananindeua, Pará, Brazil
| | - PF Vasconcelos
- Instituto Nacional de Ciência e Tecnologia em Dengue, Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Bioquímica e Imunologia, Belo Horizonte and Instituto Nacional de Ciência e Tecnologia para Febres Hemorrágicas Virais (INCT-FHV), Instituto Evandro Chagas, Ministério da Saúde, Ananindeua, Pará, Brazil
| | - JL Muñoz-Jordán
- Centers for Disease Control and Prevention, San Juan, Puerto Rico, US
| | - GA Santiago
- Centers for Disease Control and Prevention, San Juan, Puerto Rico, US
| | - R Ocazionez
- Universidad Industrial de Santander, Santander, Colombia
| | - L Gehrke
- Massachusetts Institute of Technology. Division of Heath Science and Technology. Cambridge, MA, US
| | - EJ Lefkowitz
- University of Alabama at Birmingham, Birmingham, AL. Current address BEP: University of Texas Southwestern Medical Center, Dallas, TX, US
| | | | - MR Henn
- Broad Institute. Cambridge, MA, US
| | - I Bosch
- University of Massachusetts Medical School, Worcester, MA, US. Current address DJS: Tuft University Veternary School, North Grafton, MA
| |
Collapse
|
2
|
Albánez S, Ruiz-Sáez A, Boadas A, de Bosch N, Porco A. Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations. Haemophilia 2011; 17:e913-8. [PMID: 21371196 DOI: 10.1111/j.1365-2516.2011.02500.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Haemophilia A is caused by mutations in the gene encoding coagulation factor VIII (FVIII). In severe Haemophilia A (sHA), two inversions are responsible for approximately 50% of the genetic alterations (intron 22 and intron 1 inversions). The other mutations are extremely diverse and each affected family generally has its own mutation. Our aim was to detect the genetic alterations present in the FVIII gene (F8) in 54 unrelated male patients with sHA in Venezuela. We initially detected the presence of the intron 22 inversion by performing inverse PCR, and the negative patients for this inversion were analysed for the intron 1 inversion by PCR. Patients negative for both inversions were analysed using Conformation Sensitive Gel Electrophoresis for mutations in all exons, promoter region and 3'-UTR. sHA causative mutations were identified in 49 patients. Intron-22 and -1 inversions were detected in 41% and 0% of patients respectively. Besides these two mutations, 25 different mutations were identified, including nine nonsense, four small deletions, two small insertions, four missense, three splicing mutations and three large deletions. Seven novel mutations were identified, including two nonsense mutations, two small deletions, one small insertion, one missense mutation and one splicing mutation. Thirty one percent of the patients with identified mutations developed inhibitors against exogenous FVIII. This is the first report of F8 mutations in patients with sHA in Venezuela; the data from this study suggests that the spectrum of gene defects found in these patients is as heterogeneous as reported previously for other populations.
Collapse
Affiliation(s)
- S Albánez
- Laboratorio de Genética Molecular Humana B, Universidad Simón Bolívar, Caracas, Venezuela
| | | | | | | | | |
Collapse
|
3
|
Lopez-Johnston JC, de Bosch N, Scannone H, Rodríguez-Acosta A. Inhibition of adrenaline and adenosine diphosphate induced platelet aggregation by Lansberg's hognose pit viper (Porthidium lansbergii hutmanni) venom. Ann Hematol 2007; 86:879-85. [PMID: 17891398 DOI: 10.1007/s00277-007-0354-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2007] [Accepted: 07/18/2007] [Indexed: 11/29/2022]
Abstract
The haemostatic components of venom from the genus Porthidium has been poorly studied, although it is known that severe manifestations occur when humans are envenomed, which include invasive oedema and disseminated ecchymosis. The effects of venom on blood platelets are commonly studied and are normally carried out with platelet-rich plasma (PRP). A series of crude venom dilutions was used to determine the effects of adenosine diphosphate (2 microM) and adrenaline (11 microM) induced platelet aggregation. Venom of Porthidium lansbergii hutmanni was fractioned by anionic exchange chromatography, and the fractions were also used to determine the 50% inhibition of adenosine diphosphate (ADP) and adrenaline-induced platelet aggregating dose (AD50). Crude venom has more effect in inhibiting adrenaline-induced aggregation (AD50 = 0.0043 microg) followed by the adenosine diphosphate (AD50 = 17 microg). Peaks I and II obtained by chromatography also inhibited adrenaline-induced platelet aggregation with an AD50 of 3.2 and 0.013 microg, respectively, and both peaks inhibited ADP-induced platelet aggregation with an AD50 of 10 microg. The main purpose of this work was to characterise the in vitro effects caused by P. lansbergii hutmanni crude venom and its fractions on the platelet aggregation mediated by adrenaline and ADP agonists.
Collapse
Affiliation(s)
- J C Lopez-Johnston
- Laboratorio de Investigaciones, Facultad de Farmacia, Universidad Central de Venezuela, Caracas, Venezuela
| | | | | | | |
Collapse
|
5
|
Abstract
Most of the world's haemophilia population lives in countries with few medical or financial resources. As such, they cannot easily obtain viral-inactivated clotting product. Many patients are treated with cryoprecipitate made from locally supplied blood. The reasoning for using cryoprecipitate, instead of viral-inactivated products, is based on an unspoken belief that because blood banks can provide reasonably safe products by using modern testing procedures, transmission of HIV and other blood-borne viruses is rare. However, the risk of acquiring a blood-borne infection increases with every exposure, and haemophilia patients treated with cryoprecipitate or fresh-frozen plasma are exposed to hundreds or thousands of donors during their lifetime. The risk that a person infected with HIV will donate blood during the 'window period' is directly related to the incidence of HIV in the country where the donation occurs. To demonstrate the extent of this problem, we devised a model for estimating the risk that a person with haemophilia will encounter HIV-contaminated cryoprecipitate based on the years of treatment and the underlying incidence rate of HIV among blood donors. We applied the model to two countries with different incidence rates of HIV: Venezuela and the United States. We found that a person with haemophilia who receives monthly infusions of cryoprecipitate prepared from plasma of 15 donors over a lifetime of treatment (60 years) is at significant risk of being exposed to HIV. In the United States there is a 2% risk of being exposed to HIV-contaminated blood product, and in Venezuela, the percentage of risk is 40%. Given this degree of risk, medical care providers should carefully evaluate the use of cryoprecipitate except in emergencies or when no viral-inactivated products are available.
Collapse
Affiliation(s)
- B Evatt
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | | | | | | |
Collapse
|
6
|
Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost 1994; 72:180-5. [PMID: 7831648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
von Willebrand factor gene deletions were characterized in four patients with severe type III von Wilebrand disease and alloantibodies to von Willebrand factor. A PCR-based strategy was used to characterize the boundaries of the deletions. Identical 30 kb von Willebrand factor gene deletions which include exons 33 through 38 were identified in two siblings of one family by this method. A small 5 base pair insertion (CCTGG) was sequenced at the deletion breakpoint. PCR analysis was used to detect the deletion in three generations of the family, including two family members who are heterozygous for the deletion. In a second family, two type III vWD patients, who are distant cousins, share an approximately 56 kb deletion of exons 22 through 43. The identification and characterization of large vWF gene deletions in these type III vWD patients provides further support for the association between large deletions in both von Willebrand factor alleles and the development of inhibitory alloantibodies.
Collapse
Affiliation(s)
- D J Mancuso
- Howard Hughes Medical Institute, Jewish Hospital of St. Louis
| | | | | | | | | | | |
Collapse
|